title: Not traditional prognostic factors in human conventional renal carcinoma.
abstract: The evaluation of know prognostic factors is an essential step of the assessment of the patients affected by primary renal carcinoma. As long as the major biological mechanisms of renal carcinomas remain unknown, it will be impossible to achieve an accurate prognostic judgement. The TNM classification has always been the main source of information. Nevertheless, recently several investigations evaluated the prognostic power of serum and cellular markers. The aim of this study is to identify those markers which show statistical reliability and can be used in the clinical practice. A literature search was performed on MEDLINE to identify potential not traditional prognostic factors for patients with renal cell carcinoma edited from January 1997 through April 2000 using prognosis and clear cell carcinoma and kidney as keywords. We considered also articles cited in references of first selected manuscript. The analysis of serum and cellular prognostic markers does not allow the identification of specific factors, reliable, independent, easy to dose, widely useful and whose informations are repeatable. Currently classical prognostic factors (staging, grading, hystologic type, patient clinical conditions, anaemia, presentation modalities, etc.) represent the only useful elements after surgical time in RCC patients. Among serum prognostic factors, CRP and ferritin play a crucial role. These proteins appear ideal in monitoring the disease over time, due to simple test execution and specimens repeatability. Among RCC molecular markers, proliferation index result promising for their reliability and reproducibility, the easy dosage and high series number tested. Literature data suggest that the ideal marker for renal carcinomas has not been identified yet. However, C-reactive protein, ferritin and the proliferative activity indexes (Ki67 and AgNOR) appear to be, at present, the best prognostic tools. To confirm obtained results and to use biomolecolar markers on a routinary base further studies on wide surgical series will be required. The improvement of technical tool and costs reduction represent also a necessary step toward the identification of efficient prognostic markers in RCC.
authors.affiliation: Clinica Urologica, Università degli Studi di Napoli Federico II, Naples, Italy. lucacindolo@virgilio.it
authors.forename: L
authors.initials: L
authors.lastname: Cindolo
authors.forename: M
authors.initials: M
authors.lastname: Cantile
authors.forename: R
authors.initials: R
authors.lastname: Galasso
authors.forename: M
authors.initials: M
authors.lastname: Marsicano
authors.forename: G
authors.initials: G
authors.lastname: Napodano
authors.forename: V
authors.initials: V
authors.lastname: Altieri
mesh_terms: D015415:Biomarkers / Q000097:blood; D002292:Carcinoma, Renal Cell / Q000097:blood; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood; D011379:Prognosis
chemical_list: D015415:Biomarkers